<i>FGFR1</i> Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer

• Egile Nagusiak: María Gaibar (Egilea), Apolonia Novillo (Egilea), Alicia Romero-Lorca (Egilea), Diego Malón (Egilea), Beatriz Antón (Egilea), Amalia Moreno (Egilea), Ana Fernández-Santander (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2022-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

HER2-positive breast cancer (BC) is an aggressive subtype that affects 20-25% of BC patients. For these patients, neoadjuvant therapy is a good option that targets a pathological complete response (pCR) and more breast-conserving surgery. In effect, the outcomes of patients with HER2-positive BC hav...